MultiCell Appoints Leading Stem Cell Expert to its Scientific Advisory Board
Wednesday April 6, 8:30 am ET
SAN DIEGO--(BUSINESS WIRE)--April 6, 2005--MultiCell Technologies, Inc. (OTCBB:MUCL - News), a leading supplier of non-tumorigenic immortalized human hepatocytes, announced today that it has appointed Markus Grompe, MD to the newly formed Stem Cell Panel of its Scientific Advisory Board. The Company's Scientific Advisory Board is expected to play an important role in the commercialization of MultiCell's technology and will assist the Company in pursuing licensing opportunities. Dr. Grompe is widely regarded as one of the world's foremost liver and stem cell authorities. He holds U.S. Patent No. 6,12,708 on liver regeneration using pancreatic cells. Dr. Grompe was appointed as a Director of the Oregon Stem Cell Center in 2004.
ADVERTISEMENT
"Dr. Grompe is widely acknowledged as one of the world's foremost liver and stem cell experts," stated Stephen Chang, Ph.D., President of MultiCell. "We are proud to have such a noted expert join us. We welcome his invaluable guidance as we establish a stem cell panel on the Scientific Advisory Board to help plan the future of MultiCell."
Dr. Grompe has taught in the Department of Molecular and Medical Genetics and the Department of Pediatrics, Oregon Health Sciences University, Portland, Oregon since 1991. From 1983 - 1984 he was a Research Assistant in the Department of Clinical Physiology of the University of Ulm. In 1987 he completed a Pediatric Residency at the Oregon Health Sciences University, Portland, Oregon. From 1987-1991 he was a Genetics Fellow at Baylor College of Medicine in Houston, Texas. He is Board certified in Clinical Genetics, Biochemical and Molecular Genetics. He has been licensed to practice medicine in West Germany and the European Community since 1983 and became a United States MD in 1984.
Dr. Grompe is a Diplomate of the American Board of Human Genetics, a member of the American Society for Investigative Pathology, a member of the Society for Inborn Metabolic Disease, a member of the Western Society for Pediatric Research, a member of the Society for Pediatric Research, a member of the American Society for Human Gene Therapy, and a member of the International Society for Stem Cell Research. He also serves on the American Society for Human Gene Therapy Committee on Stem Cells; the NIH Beta cell consortium external advisory pane; the NIH Study Section on Gene Therapy and Inborn Errors (Chairperson); the March of Dimes Research grant review panel; the Society for Pediatric Research, E. Mead Johnson Award Selection Committee; and the Board of Directors of the International Society for Stem Cell Research. Dr. Grompe was Associate Editor on the Editorial Board of the American Journal of Human Genetics from 1996 to 1998.
Dr. Grompes' recent honors include the E. Mead Johnson Award for research in Pediatrics in 2002 and the Award of Merit from the Fanconi Anemia Research Fund in 2002. Dr. Grompe has authored or co-authored 99 peer-reviewed articles and 32 reviews, book chapters and editorials.
A native of New Zealand, he received his education at the University of Ulm School of Medicine, Ulm, West Germany and was a visiting student at the University of Oregon Health Sciences Center in Portland, Oregon.
MultiCell holds a patent on novel strategies for isolation of adult human liver stem cells. Liver stem cells may play a key role in transplantation for tissue regeneration as well as other diagnostic and therapeutic applications. The use of liver stem cells to treat diseases, such as Hepatitis C, may greatly enhance quality of life and avoid the need for costly whole organ liver transplantation. MultiCell believes its stem cell technique is unique within the cell therapy market. Obtaining stem cells from adult tissues avoids the ethical and contamination issues often associated with embryonic stem cells.
For information about MultiCell call 401-738-7560 or see www.multicelltech.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies, Inc.
Dr. Stephen M. Chang, 401-738-7560
or
CEOcast, Inc. for MutiCell Technologies
Ed Lewis, 212-732-4300 x225
--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.
biz.yahoo.com |
